BACKGROUND Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We report health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis in the phase 3 open-label, long-term extension study, OCTAVE Open. METHODS The Inflammatory Bowel Disease Questionnaire (IBDQ), EuroQoL-5 Dimensions Health Questionnaire, and 36-Item Short Form Survey scores were analyzed up to month (M) 72 in 4 subpopulations: patients in remission at baseline (maintenance remitters) assigned tofacitinib 5 mg twice daily and patients not in remission at baseline (maintenance nonremitters, maintenance treatment failures, and induction nonresponders [IndNRs]) assigned tofacitinib 10 mg twice dail...
Background: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential...
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment o...
Background Tofacitinib, an oral small molecule Janus kinase inhibitor, has been approved in 2018 fo...
BACKGROUND Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulce...
Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aim:Thi...
BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis...
Background: ulcerative colitis is a chronic inflammatory disease of the colon for which current trea...
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment o...
Recent advances in the understanding of the pathophysiology of ulcerative colitis (UC) have led to t...
BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis...
peer reviewedIntroduction: Tofacitinib, an oral Janus kinase inhibitor, has been approved in 2018 fo...
Background: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential...
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment o...
Background Tofacitinib, an oral small molecule Janus kinase inhibitor, has been approved in 2018 fo...
BACKGROUND Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulce...
Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aim:Thi...
BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis...
Background: ulcerative colitis is a chronic inflammatory disease of the colon for which current trea...
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment o...
Recent advances in the understanding of the pathophysiology of ulcerative colitis (UC) have led to t...
BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis...
peer reviewedIntroduction: Tofacitinib, an oral Janus kinase inhibitor, has been approved in 2018 fo...
Background: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential...
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment o...
Background Tofacitinib, an oral small molecule Janus kinase inhibitor, has been approved in 2018 fo...